VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Virginia Retirement Systems acquired 17,500 ANI Pharmaceuticals shares worth approximately $1.45 million, while institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals beat quarterly expectations with $2.21 EPS versus $2.04 expected and revenue of $266.04 million, up 25.8% year over year.
• ANIP recently traded at $70.19, down 1.8%; analysts maintain a “Moderate Buy” consensus with an average price target of $105.57, though some firms recently lowered ratings or targets.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 17,500 shares of the specialty pharmaceutical company's stock, valued at approximately $1,449,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.08% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the first quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock valued at $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after purchasing an additional 423 shares during the period. Jane Street Group LLC acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. Finally, Norges Bank bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $625,000. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Down 1.8%

Shares of ANIP stock opened at $70.19 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $99.39. The firm has a market capitalization of $1.61 billion, a PE ratio of 15.13 and a beta of 0.45. The stock has a fifty day moving average of $77.26 and a two-hundred day moving average of $78.19. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company's quarterly revenue was up 25.8% compared to the same quarter last year. During the same period last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday. They issued an "outperform" rating and a $104.00 target price on the stock. Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research report on Monday, August 10th. Finally, Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $105.57.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen Carey sold 3,313 shares of the business's stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $15,268,698. The trade was a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the sale, the vice president directly owned 74,424 shares of the company's stock, valued at approximately $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,425 shares of company stock worth $1,687,370 in the last 90 days. Corporate insiders own 8.10% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.